Pathophysiology and management of sensitive skin : position paper from the special interest group on sensitive skin of the International Forum for the Study of Itch (IFSI)
(2020) In Journal of the European Academy of Dermatology and Venereology 34(2). p.222-229- Abstract
The special interest group on sensitive skin of the International Forum for the Study of Itch previously defined sensitive skin as a syndrome defined by the occurrence of unpleasant sensations (stinging, burning, pain, pruritus and tingling sensations) in response to stimuli that normally should not provoke such sensations. This additional paper focuses on the pathophysiology and the management of sensitive skin. Sensitive skin is not an immunological disorder but is related to alterations of the skin nervous system. Skin barrier abnormalities are frequently associated, but there is no cause and direct relationship. Further studies are needed to better understand the pathophysiology of sensitive skin – as well as the inducing factors.... (More)
The special interest group on sensitive skin of the International Forum for the Study of Itch previously defined sensitive skin as a syndrome defined by the occurrence of unpleasant sensations (stinging, burning, pain, pruritus and tingling sensations) in response to stimuli that normally should not provoke such sensations. This additional paper focuses on the pathophysiology and the management of sensitive skin. Sensitive skin is not an immunological disorder but is related to alterations of the skin nervous system. Skin barrier abnormalities are frequently associated, but there is no cause and direct relationship. Further studies are needed to better understand the pathophysiology of sensitive skin – as well as the inducing factors. Avoidance of possible triggering factors and the use of well-tolerated cosmetics, especially those containing inhibitors of unpleasant sensations, might be suggested for patients with sensitive skin. The role of psychosocial factors, such as stress or negative expectations, might be relevant for subgroups of patients. To date, there is no clinical trial supporting the use of topical or systemic drugs in sensitive skin. The published data are not sufficient to reach a consensus on sensitive skin management. In general, patients with sensitive skin require a personalized approach, taking into account various biomedical, neural and psychosocial factors affecting sensitive skin.
(Less)
- author
- author collaboration
- organization
- publishing date
- 2020-02-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of the European Academy of Dermatology and Venereology
- volume
- 34
- issue
- 2
- pages
- 222 - 229
- publisher
- Elsevier
- external identifiers
-
- pmid:31660659
- scopus:85074187863
- ISSN
- 0926-9959
- DOI
- 10.1111/jdv.16000
- language
- English
- LU publication?
- yes
- id
- c5f21452-5d71-4120-bb50-08d256df785c
- date added to LUP
- 2019-11-22 10:14:02
- date last changed
- 2024-09-19 12:50:52
@article{c5f21452-5d71-4120-bb50-08d256df785c, abstract = {{<p>The special interest group on sensitive skin of the International Forum for the Study of Itch previously defined sensitive skin as a syndrome defined by the occurrence of unpleasant sensations (stinging, burning, pain, pruritus and tingling sensations) in response to stimuli that normally should not provoke such sensations. This additional paper focuses on the pathophysiology and the management of sensitive skin. Sensitive skin is not an immunological disorder but is related to alterations of the skin nervous system. Skin barrier abnormalities are frequently associated, but there is no cause and direct relationship. Further studies are needed to better understand the pathophysiology of sensitive skin – as well as the inducing factors. Avoidance of possible triggering factors and the use of well-tolerated cosmetics, especially those containing inhibitors of unpleasant sensations, might be suggested for patients with sensitive skin. The role of psychosocial factors, such as stress or negative expectations, might be relevant for subgroups of patients. To date, there is no clinical trial supporting the use of topical or systemic drugs in sensitive skin. The published data are not sufficient to reach a consensus on sensitive skin management. In general, patients with sensitive skin require a personalized approach, taking into account various biomedical, neural and psychosocial factors affecting sensitive skin.</p>}}, author = {{Misery, L. and Weisshaar, E. and Brenaut, E. and Evers, A. W.M. and Huet, F. and Ständer, S. and Reich, A. and Berardesca, E. and Serra-Baldrich, E. and Wallengren, J. and Linder, D. and Fluhr, J. W. and Szepietowski, J. C. and Maibach, H. and Honari, Golara and Le Gall-Ianotto, Christelle and Takamori, Kenji and Richters, Renée}}, issn = {{0926-9959}}, language = {{eng}}, month = {{02}}, number = {{2}}, pages = {{222--229}}, publisher = {{Elsevier}}, series = {{Journal of the European Academy of Dermatology and Venereology}}, title = {{Pathophysiology and management of sensitive skin : position paper from the special interest group on sensitive skin of the International Forum for the Study of Itch (IFSI)}}, url = {{http://dx.doi.org/10.1111/jdv.16000}}, doi = {{10.1111/jdv.16000}}, volume = {{34}}, year = {{2020}}, }